{"id":"high-dose-skq1","safety":{"commonSideEffects":[{"rate":null,"effect":"Local ocular irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye discomfort"}]},"_chembl":{"chemblId":"CHEMBL4285129","moleculeType":"Small molecule","molecularWeight":"539.72"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SkQ1 (plastoquinone derivative) is designed to cross cell membranes and concentrate in mitochondria due to its lipophilic cationic structure. Once localized to mitochondria, it acts as an electron acceptor and antioxidant, reducing mitochondrial oxidative stress and preventing cellular damage from reactive oxygen species. This mechanism is intended to slow age-related degeneration and protect against conditions driven by mitochondrial dysfunction.","oneSentence":"SkQ1 is a mitochondrial-targeted antioxidant that accumulates in mitochondria to neutralize reactive oxygen species and protect against oxidative damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:45.121Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Age-related macular degeneration (AMD)"},{"name":"Dry eye disease"},{"name":"Other age-related ocular conditions"}]},"trialDetails":[{"nctId":"NCT03764735","phase":"PHASE3","title":"Study of SkQ1 as Treatment for Dry-eye Syndrome","status":"COMPLETED","sponsor":"Mitotech, SA","startDate":"2018-12-06","conditions":"Dry Eye Syndrome","enrollment":452},{"nctId":"NCT02121301","phase":"PHASE2","title":"A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)","status":"COMPLETED","sponsor":"Mitotech, SA","startDate":"2014-04","conditions":"Keratoconjunctivitis Sicca","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Visomitin"],"phase":"phase_3","status":"active","brandName":"High dose - SkQ1","genericName":"High dose - SkQ1","companyName":"Mitotech, SA","companyId":"mitotech-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High dose SkQ1 is being studied in a clinical trial for the treatment of Keratoconjunctivitis Sicca and Dry Eye Syndrome. The trial is comparing the safety and efficacy of a high dose 1.55µg/mL SkQ1 ophthalmic solution to a low dose 0.155µg/mL SkQ1 ophthalmic solution and a placebo solution.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}